New Delhi - Japan's Daiichi Sankyo had completed its acquisition of Indian pharmaceutical major Ranbaxy Laboratories, the companies said in a joint statement Friday.

It was announced in June that the Japanese firm would be acquiring a controlling stake of 63.92 per cent in Ranbaxy, India's largest pharma firm, in an estimated 4-billion-dollar deal.

In a regulatory statement, the firms announced Friday that they had closed the deal with the final transfer of remaining equity shares of the promoters of Ranbaxy, the Singh family.

Ranbaxy would continue to operate as an independent and autonomous company under Malvinder Mohan Singh, its former chief executive-promoter, the statement said. Singh would also be a part of Daiichi's senior global management, it added.

The acquisition is part of Daiichi Sankyo's plans to enter the generic drugs market. (dpa)